14. Referenties

1.    Berden, F.A., et al., Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era. Neth J Med, 2014. 72(8): p. 388-400.
2.    European Association for the Study of the Liver. Electronic address, e.e.e., EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol, 2015.
3.    Recommendations for Testing, Managing, and Treating Hepatitis C. www.hcvguidelines.org, 2016.
4.    van der Meer, A.J., et al., Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA, 2012. 308(24): p. 2584-93.
5.    Tacke., F., et al., TREATMENT OF HCV GENOTYPE 2 WITH SOFOSBUVIR AND RIBAVIRIN RESULTS IN LOWSVR RATES IN A REALWORLD COHORT (GERMAN HEPATITIS C-REGISTRY, DHC-R). EASL abstract, 2016.
6.    Susser., S., et al., PREVALENCE AND CLINICAL IMPORTANCE OF HEPATITIS C VIRUS GENOTYPE 2 K/1B CHIMERAS. EASL abstract, 2016.
7.    Arends, J.E., et al., Treatment of acute hepatitis C virus infection in HIV+ patients: Dutch recommendations for management. Neth J Med, 2011. 69(1): p. 43-9.
8.    Lamers, M.H., et al., Treatment of hepatitis C monoinfection in adults--Dutch national guidelines. Neth J Med, 2013. 71(7): p. 377-85.
9.    EMA. Summary of prodcut characteristics: Pegasys. 2007  [cited 2015 June 5]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000395/WC500039195.pdf.
10.    Barril, G., et al., Pegylated interferon-α2a kinetics during experimental haemodialysis: impact of permeability and pore size of dialysers. Alimentary Pharmacology & Therapeutics, 2004. 20(1): p. 37-44.
11.    EMA, Summary of Product Characteristics: PegIntron. 2010.
12.    Gupta, S.K., et al., Multiple-dose pharmacokinetics of peginterferon alfa-2b in patients with renal insufficiency. British Journal of Clinical Pharmacology, 2007. 64(6): p. 726-732.
13.    EMA, Copegus: prescibing information. 2011.
14.    Bruchfeld, A., et al., Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat, 2006. 13(5): p. 316-21.
15.    Fda. Copegus : Prescribing information. 2011; Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
16.    EMA. Olysio: Product Information. 2014  [cited 2015 February 15]; Available from: http://ec.europa.eu/health/documents/community-register/2014/20140514128513/anx_128513_en.pdf.
17.    Nazario., H.E., M. Ndungu., and A.A. Modi, Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR <30 ml/min. EASL abstract, 2016.
18.    Comellas, B., Treatmet of HCV withs imeprevir associated to daclatasvir in patients with stage 4 and 5 chornic renal failure. EASL abstract, 2016.
19.    Nazario, H.E., sofosbuvir-based, ribavirin-free regimens in patients with chronic hepatitis C and end-stage renal disease: a look at safety, tolerability and efficacy. EASL abstract, 2016.
20.    EMA, Summary of Product Characteristics: Solvaldi. 2014.
21.    Saxena, V., et al., Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: real-world experience from HCV-TARGET, in Annual Meeting of the European Association for the Study of the Liver (EASL). 2015: Vienna.
22.    Gane, E.J., et al., Safety, Antiviral Efficacy, and Pharmacokinetics of Sofosbuvir in Patients With Severe Renal Impairment in Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). 2014: Boston.
23.    Nazario, H.E., M. Ndungu, and A. Modi, Safety and efficacy of sofosbuvir + simeprevir without ribavirin in hepatitis C genotype 1-infected patients with end-stage renal disease or GFR<30ml/min, in Annual Meeting of the European Association for the Study of the Liver (EASL). 2015: Vienna.
24.    Beinhardt, S., et al., Real life experience with interferon/ribavirin free antiviral treatment in renal transplant recipients and end stage renal disease patients on dialysis infected with hepatitis C virus, in Annual Meeting of the European Association for the Study of the Liver (EASL). 2015: Vienna.
25.    Desnoyer, A., et al., Sofosbuvir in haemodialysis: 400mg daily only the day of haemodialysis? , in 16th Workshop of Clinical pharmacology of HIV and Hepatitis Therapy. 2015: Washington, DC.
26.    Desnoyer, A., et al., Sofosbuvir-containing regimen for HCV infection in hemodialysis patients: 400 mg daily or only on the day of hemodialysis. EASL abstract, 2016.
27.    EMA. Daklinza: Summary of Product Characteristics. 2014; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003768/WC500172848.pdf.
28.    EMA. Summary of Product Characteristics: Viekirax. 2015  [cited 2015 June 5]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003839/WC500183997.pdf.
29.    Pockros, P.J., et al., Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: the RUBY-1 study, in Annual Meeting of the European Association for the Study of the Liver (EASL). 2015: Vienna.
30.    EMA. Summary of Product Characteristics: Exviera. 2015  [cited 2015 June 5]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003837/WC500182233.pdf.
31.    EMA. Harvoni: Product Information. 2014 November 17 [cited 2015 February 15]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003850/WC500177995.pdf.
32.    Nazario, H.E., M. Ndungu, and A.A. Modi, Sofosbuvir and Simeprevir in Hepatitis C genotype 1- patients with End-Stage Renal Disease on hemodialysis or GFR <30mL/min. Liver Int, 2015.
33.    Hundemer, G.L., et al., Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency. Infect Dis (Lond), 2015. 47(12): p. 924-9.
34.    Maan, R., et al., Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. Clin Gastroenterol Hepatol, 2016. 14(12): p. 1821-1830 e6.
35.    EMA. Summary of Product Characteristics: Zepatier. 2016 [cited 2017 May 17]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/004126/WC500211238.pdf
36.    EMA. Summary of Product Characteristics: Epclusa. 2016 [cited 2017 May 17]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004210/WC500211151.pdf.
37.    Back, D.J. and D.M. Burger, Interaction Between Amiodarone and Sofosbuvir-based Treatment for Hepatitis C Virus Infection: Potential Mechanisms and Lessons to be Learned. Gastroenterology, 2015. 149(6): p. 1315-7.
38.    Fontaine, H., et al., Bradyarrhythmias Associated with Sofosbuvir Treatment. N Engl J Med, 2015. 373(19): p. 1886-8.



index.html